Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Research article

Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression

Authors: Abilasha G. Jayathilake, Margaret F. Veale, Rodney Brain Luwor, Kulmira Nurgali, Xiao Q. Su

Published in: BMC Complementary Medicine and Therapies | Issue 1/2020

Login to get access

Abstract

Background

The currently available treatments for colorectal cancer (CRC) are often associated with serious side-effects. Therefore, the development of a novel nutraceutical agent may provide an alternative complementary therapy for CRC. Overexpression of the epidermal growth factor receptor (EGFR) associates with a range of cancers while downregulation of EGFR signalling can inhibit cancer growth. Our previous studies have shown that the free fatty acid extract (FFAE) of krill oil exhibits anti-proliferative and pro-apoptotic properties. This study determines the effects of krill oil extract on the migration of human CRC cells, and its potential role in modulating EGFR signalling pathway and the expression of programmed death ligand 1 (PD-L1).

Methods

Human CRC cells, DLD-1 and HT-29 were treated with FFAE of KO at 0.03 and 0.12 μL/100 μL for 8 or 24 h. Cell migration was determined by Boyden chamber migration assay. The expression of EGFR, phosphorylated EGFR (pEGFR), protein kinase B (AKT), phosphorylated AKT (pAKT), extracellular signal regulated kinase (ERK1/2), phosphorylated ERK1/2 (pERK1/2) as well as PD-L1 were assessed by western blotting and immunohistochemistry.

Results

The FFAE of krill oil significantly inhibited cell migration compared to ethanol-treated (vehicle control) cells (P < 0.01 to P < 0.001). At the molecular level, krill oil extract reduced the expression of EGFR, pEGFR (P < 0.001 for both) and their downstream signalling, pERK1/2 and pAKT (P < 0.01 to P < 0.001) without altering total ERK 1/2 and AKT levels. In addition, the expression of PD-L1 was reduced by 67 to 72% (P < 0.001) following the treatment with krill oil extract.

Conclusion

This study has demonstrated that krill oil may be a potential therapeutic/adjunctive agent for CRC attributed to its anti-migratory effects.. The potential anti-cancer properties of krill oil are likely to be associated with the downregulation of EGFR, pEGFR and their downstream pERK/ERK1/2 and pAKT/AKT signalling pathways along with the downregulation of PD-L1.
Literature
1.
2.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.PubMedCrossRef
3.
4.
Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–808.PubMedPubMedCentralCrossRef
5.
Brouwer NPM, Bos A, Lemmens V, Tanis PJ, Hugen N, Nagtegaal ID, De Wilt JHW, Verhoeven RHA. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018;143(11):2758–66.PubMedPubMedCentralCrossRef
6.
Inada R, Nagasaka T, Watanabe A, Yagi T, Mori Y, Kondo Y, Kishimoto H, Umeda Y, Fujiwara T. Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes. BMJ Open Gastroenterol. 2017;4(1):e000146.PubMedPubMedCentralCrossRef
7.
8.
Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of Cancer chemotherapy: anything new to improve tolerance and reduce Sequelae? Front Pharmacol. 2018;9:245.PubMedPubMedCentralCrossRef
9.
10.
Morin-Ben SHV. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibiters in Treatment of Metastatic Non-Small Cell Lung Cancer,with a Focus on Afatinib. Front Oncol. 2017;7:97.CrossRef
11.
Fluckiger A, Dumont A, Derangere V, Rebe C, de Rosny C, Causse S. Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFalpha. Oncogene. 2016;35(35):4611–22.PubMedCrossRef
12.
Miccadei S, Masella R, Mileo AM, Gessani S. Omega3 Polyunsaturated Fatty Acids as Immunomodulators in Colorectal Cancer: New Potential Role in Adjuvant Therapies. Frontiers Immunol. 2016;7:486.CrossRef
13.
Tou JC, Jaczynski J, Chen YC. Krill for human consumption: nutritional value and potential health benefits. Nutr Rev. 2007;65(2):63–77.PubMedCrossRef
14.
Winther B, Hoem N, Berge K, Reubsaet L. Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba. Lipids. 2011;46(1):25–36.PubMedCrossRef
15.
Sung HH, Sinclair AJ, Lewandowski PA, Su XQ. Postprandial long-chain n-3 polyunsaturated fatty acid response to krill oil and fish oil consumption in healthy women: a randomised controlled, single-dose, crossover study. Asia Pac J Clin Nutr. 2018;27(1):148–57.PubMed
16.
Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vic H, Pedersen JI. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46(1):37–46.PubMedCrossRef
17.
Su XU, Tanalgo P, Bustos M, Dass CR. The effect of krill oil and n-3 polyunsaturated fatty acids on human osteosarcoma cell proliferation and migration. Curr Drug Targets. 2018;19(5):479–86.PubMedCrossRef
18.
Jayathilake AG, Senior PV, Su XQ. Krill oil extract suppresses cell growth and induces apoptosis of human colorectal cancer cells. BMC Complement Altern Med. 2016;16(1):328.PubMedPubMedCentralCrossRef
19.
Jayathilake AG, Kadife E, Luwor RB, Nurgali K, Su XQ. Krill oil extract suppresses the proliferation of colorectal cancer cells through activation of caspase 3/9. Nutr Metab (Lond). 2019;16:53.CrossRef
20.
Zhu JJ, Shi JH, Qian WB, Cai ZZ, Li D. Effects of krill oil on serum lipids of hyperlipidemic rats and human SW480 cells. Lipids Health Dis. 2008;7:30.PubMedPubMedCentralCrossRef
21.
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8(12):1197–206.PubMedCrossRef
22.
Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int. 2013;2013:546318.PubMedPubMedCentralCrossRef
23.
Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002;99(3):1521–6.PubMedPubMedCentralCrossRef
24.
Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009;28(2):306–12.PubMedCrossRef
25.
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–8.PubMedCrossRef
26.
Ding Y, Mullapudi B, Torres C, Mascarinas E, Mancinelli G, Diaz AM, McKinney R, Barron M, Schultz M, Heiferman M, Wojtanek M, Adraian K, DeCant B, Rao S, Ouellette M, Taso MS, Bentrem DJ, Grippo PJ. Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway. Nutrients. 2018;10(9):1289. https://​doi.​org/​10.​3390/​nu10091289.
27.
28.
Salimon J, Abdullah BM, Salih N. Hydrolysis optimization and characterization study of preparing fatty acids from Jatropha curcas seed oil. Chem Cent J. 2011;5:67.PubMedPubMedCentralCrossRef
29.
Xie DGM, Wei W, Jin J, Wang X, Wang X, Jin Q. Antarctic krill (Euphausia superba) oil: a comprehensive review of chemical composition, extraction technologies, health benefits, and current application. Compr Rev Food Sci Food Saf. 2019;18(2):514–34.CrossRef
30.
Zheng W, Wang X, Cao W, Yang B, Mu Y, Dong Y. E-configuration structures of EPA and DHA derived from Euphausia superba and their significant inhibitive effects on growth of human cancer cell lines in vitro. Prostaglandins Leukot Essent Fatty Acids. 2017;117:47–53.PubMedCrossRef
31.
Zheng W, Li J, Wang X, Yuan Y, Zhang J, Xiu Z. Effects of Antarctic krill docosahexaenoic acid on MCF-7 cell migration and invasion induced by the interaction of CD95 with caveolin-1. Life Sci. 2018;192:270–7.PubMedCrossRef
32.
Lee JY, Sim TB, Lee JE, Na HK. Chemopreventive and chemotherapeutic effects of fish oil derived Omega-3 polyunsaturated fatty acids on Colon carcinogenesis. Clinical nutrition research. 2017;6(3):147–60.PubMedPubMedCentralCrossRef
33.
Eltweri AM, Thomas AL, Metcalfe M, Calder PC, Dennison AR, Bowrey DJ. Potential applications of fish oils rich in omega-3 polyunsaturated fatty acids in the management of gastrointestinal cancer. Clin Nutr. 2016;36(1):65–78.PubMedCrossRef
34.
Park JM, Kwon SH, Han YM, Hahm KB, Kim EH. Omega-3 polyunsaturated fatty acids as potential chemopreventive agent for gastrointestinal cancer. J Cancer Prevention. 2013;18(3):201–8.CrossRef
35.
Fuentes NR, Salinas ML, Kim E, Chapkin RS. Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1668–78.PubMedCrossRef
36.
Michalak A, Mosinska P, Fichna J. Polyunsaturated fatty acids and their derivatives: therapeutic value for inflammatory, functional gastrointestinal disorders, and colorectal Cancer. Front Pharmacol. 2016;7:459.PubMedPubMedCentralCrossRef
37.
38.
Zhang C, Yu H, Ni X, Shen S, Das UN. Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes. PLoS One. 2015;10(4):e0123256.PubMedPubMedCentralCrossRef
39.
Giros A, Grzybowski M, Sohn VR, Pons E, Fernandez-Morales J, Xicola RM, Sethi P, Grzybowski J, Goel A, Boland CR, Gassull MA, Llor X. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic. Cancer Prev Res (Phila). 2009;2(8):732–42.CrossRef
40.
Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2012;61(1):135–49.PubMedCrossRef
41.
Rogers KR, Kikawa KD, Mouradian M, Hernandez K, McKinnon KM, Ahwah SM, Pardini RS. Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis. 2010;31(9):1523–30.PubMedCrossRef
42.
Turk HF, Chapkin RS. Membrane lipid raft organization is uniquely modified by n-3 polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):43–7.PubMedCrossRef
43.
Matucci-Cerinic M, Casini A. Ketoprofen vs etofenamate in a controlled double-blind study: evidence of topical effectiveness in soft tissue rheumatic pain. Int J Clin Pharmacol Res. 1988;8(3):157–60.PubMed
44.
Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry R, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.PubMedCrossRef
45.
Schley PD, Jijon HB, Robinson LE, Field CJ. Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2005;92(2):187–95.PubMedCrossRef
46.
Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle. 2009;8(8):1168–75.PubMedPubMedCentralCrossRef
47.
Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41.PubMedPubMedCentralCrossRef
48.
Millington GW. Mutations of the BRAF gene in human cancer, by Davies et al. (nature 2002; 417: 949-54). Clin Exp Dermatol. 2013;38(2):222–3.PubMedCrossRef
49.
Sun H, Hu Y, Gu Z, Owens RT, Chen YQ, Edwards IJ. Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis. 2011;32(10):1518–24.PubMedPubMedCentralCrossRef
50.
Cao W, Ma Z, Rasenick MM, Yeh S, Yu J. N-3 poly-unsaturated fatty acids shift estrogen signaling to inhibit human breast cancer cell growth. PLoS One. 2012;7(12):e52838.PubMedPubMedCentralCrossRef
51.
Serini S, Ottes Vasconcelos R, Fasano E, Calviello G. Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer. Expert Opin Ther Targets. 2016;20(7):843–58.PubMedCrossRef
52.
53.
54.
Szymonowicz K, Oeck S, Malewicz NM, Jendrossek V. New insights into protein kinase b/akt signaling: role of localized akt activation and compartment-specific target proteins for the cellular radiation response. Cancers. 2018;10(3):78.
55.
Henderson V, Smith B, Burton LJ, Randle D, Morris M, Odero-Marah VA. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adhes Migr. 2015;9(4):255–64.CrossRef
56.
Arteaga CL. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Curr Top Microbiol Immunol. 2010;347:189–208.PubMedPubMedCentral
57.
Shaw R, Festing MF, Peers I, Furlong L. Use of factorial designs to optimize animal experiments and reduce animal use. ILAR J. 2002;43(4):223–32.PubMedCrossRef
58.
59.
Calvo E, Bolos V, Grande E. Multiple roles and therapeutic implications of Akt signaling in cancer. OncoTargets Therap. 2009;2:135–50.
60.
Yin Y, Sui C, Meng F, Ma P, Jiang Y. The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway. Lipids Health Dis. 2017;16(1):87.PubMedPubMedCentralCrossRef
61.
Shin S, Jing K, Jeong S, Kim N, Song KS, Heo JY, Park H, SeoK S, Han J, Park J, Kweon GR, Kiel Park S, Wu T, Hwang BD, Lim K. The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. BioMed Res Int. 2013;2013:568671.PubMedPubMedCentralCrossRef
62.
Huang LH, Chung HY, Su HM. Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line. BMC Cancer. 2017;17(1):890.PubMedPubMedCentralCrossRef
63.
64.
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52.PubMedCrossRef
65.
Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW, Chen L, Pardoll DM, Drake CG. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007;110(1):186–92.PubMedPubMedCentralCrossRef
66.
Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004;24(4):229–37.PubMedCrossRef
67.
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37(34):4639–61.PubMedPubMedCentralCrossRef
68.
Lastwika KJ, Wilson W, 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM,Yao S, Liu Ln, Gills JJ,Dennis PA. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res 2016;76(2):227–238.
69.
70.
Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. PLoS One. 2016;11(11):e0166626.PubMedPubMedCentralCrossRef
71.
Liang H, Liu X, Wang M. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. Onco Targets Ther. 2018;11:6189–96.PubMedPubMedCentralCrossRef
72.
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu Z. Huang JA. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016;49(4):1360–8.PubMedCrossRef
73.
Sasada T, Azuma K, Ohtake J, Fujimoto Y. Immune responses to epidermal growth factor receptor (EGFR) and their application for Cancer treatment. Front Pharmacol. 2016;7:405.PubMedPubMedCentralCrossRef
74.
Yin X, Wang Y, Bai S, Feng W, Feng L, Zhao W, Wei M, Pang X, Liu S, Chen H, He F, Cheng Y, Yin J, Zhang D, Zheng J, Wang L, Fan X, Wan X. Epidermal growth factor receptor stabilizes programmed death ligand 1 by glycosylation in colorectal cancer with microstatellite instability status. J Bio-X Research. 2019;2(1):1–8.
75.
Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10(6):910–23.PubMedCrossRef
76.
Chen H-N, Liang K-H, Lai J-K, Lan C-H, Liao M-Y, Hung S-H, Chuang Y-T, Chen K-C, Wei-FuW T, Wu HC. EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway. Cancer Res. 2020;80(22):5035–50.PubMedCrossRef
77.
Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189–202.PubMedPubMedCentralCrossRef
Metadata
Title
Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression
Authors
Abilasha G. Jayathilake
Margaret F. Veale
Rodney Brain Luwor
Kulmira Nurgali
Xiao Q. Su
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2020
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-020-03160-7

Other articles of this Issue 1/2020

BMC Complementary Medicine and Therapies 1/2020 Go to the issue

Research article

Protocatechuic aldehyde from Salvia miltiorrhiza exhibits an anti-inflammatory effect through inhibiting MAPK signalling pathway

Research article

Network Pharmacology Approach to Uncover the Mechanism Governing the Effect of Radix Achyranthis Bidentatae on Osteoarthritis

Research article

Genistein and exercise modulated lipid peroxidation and improved steatohepatitis in ovariectomized rats

Research article

A botanical from the antiproliferative Cameroonian spice, Imperata cylindrica is safe at lower doses, as demonstrated by oral acute and sub-chronic toxicity screenings

Research article

Anti-inflammatory effect of Salsola komarovii extract with dissociated glucocorticoid activity

Research article

Mitochondrial dependent pathway is involved in the protective effects of carboxymethylated chitosan on nitric oxide-induced apoptosis in chondrocytes